Pipeline
| Focused Indication | Program | Modality | Molecule / Product | Discovery / Preclinical | Clinical Development | Approved / Launched |
|---|---|---|---|---|---|---|
|
Hera-203 |
Diagnostic |
Innovative
Non-invasive Diagnostic |
 |
|
|
|
|
Hera-003 |
Drug |
Innovative
Non-hormonal Therapeutic mAb |
|
|
|
|
|
Hera-201 |
Diagnostic |
Innovative
Endometrial Receptivity Analysis Test |
 |
|
|
|
|
Hera-210 |
Diagnostic and Device |
Innovative
Oocyte Quality Test + Oocyte Quality Improvement Device |
|
|
|
|
|
Hera-001 |
Drug |
Innovative
Non-antibiotic, Engineered Bacteria |
|
|
|
| Focused Indication | Program | Modality | Molecule / Product | Commercial Right | Launched |
|---|---|---|---|---|---|
|
Endometriosis (Endo) |
Hera-203 |
Diagnostic |
Innovative
Non-invasive Diagnostic |
Greater China |
2023 (LDT) 2028 (IVD) |
|
Hera-003 |
Drug |
Innovative
Non-hormonal Therapeutic mAb |
Global |
2030 (BLA) |
|
|
Infertility |
Hera-201 |
Diagnostic |
Innovative
Endometrial Receptivity Analysis |
Greater China |
Launched (LDT) |
|
Hera-210 |
Diagnostic and Device |
Innovative
Oocyte Quality Test + Oocyte Quality Improvement Device |
APAC * |
Launched (HK LDT) 2029 (IVD) |
|
|
Bacterial Vaginosis (BV) |
Hera-001 |
Drug |
Innovative
Non-antibiotic, Engineered Bacteria |
Global |
2030 (NDA) |
* Can be expanded to US and EU
